How long has Entyvio been on the market?
Entyvio was launched in both the United States and European Union markets in June 2014. Entyvio, from Takeda Pharmaceuticals, was first approved by the U.S. Food and Drug Administration (FDA) on May 20, 2014. It is used for maintenance treatment of ulcerative colitis and Crohn's disease.
The U.S. approval timeline is as follows:
- In June 2013, Takeda Pharmaceuticals submitted a Biological License Application (BLA) to the FDA for the approval of Entyvio.
- It gained a priority review status from the FDA in September 2014 for the treatment of ulcerative colitis, and was fully approved for both ulcerative colitis and Crohn’s disease on May 20, 2014.
- Entyvio is also approved in other countries, including Canada, China, and Japan for treatment of both ulcerative colitis and Crohn’s disease.
Learn More: Drug Approval History for Entyvio
What is Entyvio approved to treat?
Entyvio (vedolizumab) is a biologic therapy approved by the FDA to be used adults for the treatment of Crohn's disease and ulcerative colitis. It is classified as an integrin receptor antagonist and works by preventing certain white blood cells from entering into your GI tract (intestine). This helps to control your inflammation (swelling) and symptoms.
Entyvio is not to be used as first-line therapy, but is indicated when one or more standard therapies, such as corticosteroids, immunomodulators, or TNF blockers have not been adequate for treatment.
After the first intravenous (IV) dose, it is given again at 2 and 6 weeks, then every eight weeks thereafter as a 30 minute IV infusion. Subcutaneous (SC) formulations, which are injected under the skin, are also approved in the U.S., Europe and Canada.
In the U.S, Entyvio subcutaneous formulation is approved for maintenance (long-term) treatment in adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease after induction therapy with intravenous (IV) Entyvio. Initial induction therapy with IV Entyvio is still required.
The subcutaneous form for UC use comes as a single-dose, prefilled pen or syringe. Patients or caregivers can injection Entyvio subcutaneously at home after training on the injection technique.
This is not all the information you need to know about Entyvio (vedolizumab) for safe and effective use and does not take the place of your healthcare provider's directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.
Related questions
References
- Entyvio [Prescribing Information]. Revised 04/2024. Takeda Pharmaceuticals. Lexington, MA. Accessed April 22, 2024 at https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1
- Takeda.com. Our History. Accessed April 22, 2024 https://www.takeda.com/about/our-company/history/
- European Commission Approves Subcutaneous Entyvio for use as Maintenance Therapy in Ulcerative Colitis or Crohn’s Disease. May 8, 2020. Press release. Accessed April 22, 2024 at https://www.takeda.com/newsroom/newsreleases/2020/european-commission-approves-subcutaneous-entyvio-for-use-as-maintenance-therapy-in-ulcerative-colitis-or-crohns-disease/
- Entyvio.com. Takeda Pharmaceuticals, Inc. Accessed April 22, 2024 at https://www.entyvio.com/
Read next
Can I drink alcohol while taking Entyvio?
Although there is no indication that alcohol and Entyvio (vedolizumab) have unsafe interactions, you should ask your doctor before drinking alcohol while taking Entyvio. Continue reading
Can I take antibiotics while on Entyvio?
The use of Entyvio (generic name: vedolizumab) is not recommended in patients with an active, severe infection until the infection is controlled. Your doctor may consider withholding your Entyvio treatment if you develop a severe infection while on treatment with Entyvio. Your doctor will be able to best decide if you need to take an antibiotic or stop Entyvio treatment. Do not stop taking Entyvio without speaking to your doctor. Continue reading
Entyvio and the COVID vaccine, what should I know?
The Crohn’s & Colitis Foundation recommends that all patients taking Entyvio get vaccinated against COVID-19 with a COVID-19 vaccine, unless advised otherwise by their doctor. Continue reading
Related medical questions
- Does Entyvio cause weight gain?
- Does Entyvio increase the risk of cancer?
- Does Entyvio cause joint pain?
- Will I lose weight with Entyvio?
- How long does an Entyvio infusion take?
- Can Entyvio be given at home?
- Is Entyvio used to treat ulcerative colitis?
- Does Medicaid cover Entyvio?
- Is Entyvio used to treat Crohn’s disease?
- How is Entyvio administered?
- Can Entyvio cause hair loss?
Drug information
Related support groups
- Entyvio (21 questions, 33 members)
- Vedolizumab (6 questions, 5 members)
- Ulcerative Colitis (64 questions, 186 members)
- Crohn's Disease (51 questions, 284 members)
- Crohn's Disease - Maintenance (22 questions, 97 members)